Lexeo finalizes SUNRISE-FA 2 pivotal trial design for LX2006 in Friedreich ataxia cardiomyopathy

• Lexeo finalized the pivotal SUNRISE-FA 2 trial design for LX2006 in Friedreich ataxia cardiomyopathy, targeting accelerated-approval filing in 2028.
• Results have not been presented; a topline efficacy readout is expected in the second half of 2027, with first dosing slated by end of June.
• The study will compare a one-time gene therapy infusion against a concurrent untreated control, aiming to show improvement in heart disease progression.
• Enrollment is limited to patients with abnormal heart muscle measurements at baseline, sharpening focus on those most likely to benefit.
• Manufacturing readiness is positioned to support BLA timing, with commercial-scale product already available for dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150700PRIMZONEFULLFEED9746758) on June 15, 2026, and is solely responsible for the information contained therein.